MCC950 Sodium

Catalog No.S7809 Batch:S780904

Print

Technical Data

Formula

C20H23N2O5S.Na
Molecular Weight 426.46 CAS No. 256373-96-3
Solubility (25°C)* In vitro Water 85 mg/mL (199.31 mM)
Ethanol 85 mg/mL (199.31 mM)
DMSO Insoluble
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description MCC950 Sodium is a potent, selective inhibitor of NLRP3 with IC50 of 7.5 nM in BMDMs; but not the AIM2, NLRC4 or NLRP1 inflammasomes.
Targets
NLRP3 [1]
(in BMDM (bone marrow derived macrophages))		 NLRP3 [1]
(in HMDM)
7.5nM 8.1 nM
In vitro

MCC950 inhibits canonical and noncanonical NLRP3 activation in BMDM and HMDM cells at IC50 of 7.5 and 8.1nM. MCC950 specifically inhibits activation of NLRP3 but not the AIM2, NLRC4 or NLRP1 inflammasomes.
In vivo

MCC950 reduces interleukin-1β (IL-1β) production and attenuates the severity of experimental autoimmune encephalomyelitis (EAE). Furthermore, MCC950 treatment rescues neonatal lethality in a mouse model of CAPS and is active in ex vivo samples from individuals with Muckle-Wells syndrome.

Protocol (from reference)

Cell Assay:

[2]
  • Cell lines

    H9c2 cardiomyocyte cells

  • Concentrations

    7 nM

  • Incubation Time

    24 h

  • Method

    Cardiomyocytes were treated with NLRP3 inhibitor MCC950 for 24 h.
Animal Study:

[1]
  • Animal Models

    C57BL/6 mice

  • Dosages

    50 mg/kg

  • Administration

    i.p.

References

  • https://pubmed.ncbi.nlm.nih.gov/25686105/
  • https://pubmed.ncbi.nlm.nih.gov/35013106/

Customer Product Validation

A-C, Expression of caspase 1 and its active form caspase 1-p20, as demonstrated in representative Western blots (top) and the relative expression levels (B and C) in each group.

Data from [ , , ARTHRITIS & RHEUMATOLOGY, 2017, 69(8):1636-1646 ]

Cells were pretreated with the indicated concentrations of MCC950 followed by incubation with APAP (2mM) for additional 18 h. Cell viability was determined by MTS assay. The data are presented as the fold change compared with APAP-treated cells and expressed as mean ± SEM (n = 3).

Data from [ , , Biochem Pharmacol, 2018, 154:278-292 ]

Representative lung tissue sections stained by HE with or without Mcc950 treatment.

Data from [ , , Biochem Biophys Res Commun, 2018, 503(4):3031-3037 ]

a, b Effects of varying MCC950 concentrations (0,1,10,50 and 100 μmol/L) on NLRP3 and Caspase-1 expression within the high glucose group. The protein was measured by western blotting.GAPDH was used as an internal loading control. NG:normal control group,HG:high glucose group.Data are presented in mean ± SD, □P < 0. 05 versus normal control group, △P < 0. 05 versus high glucose group.

Data from [ , , BMC Complement Altern Med, 2018, 18(1):192 ]

Selleck's MCC950 Sodium Has Been Cited by 176 Publications

Inhibition of the NLRP3 Inflammasome With MCC950 Improves Gut Health in Huntington's Disease Mice [ J Neurochem, 2026, 170(4):e70419] PubMed: 41906693
NRG1 Suppresses NLRP3 Inflammasome Activation and Endothelial-Mesenchymal Transition in Cerebral Ischemia-Reperfusion Injury: Association with the AKT/NF-κB Pathway [ J Inflamm Res, 2026, 19:584926] PubMed: 41798642
Toxoplasma gondii effector MAF1 blocks mouse AIM2 inflammasome activation by inhibiting mtDNA release [ J Immunol, 2026, 215(2)vkaf360] PubMed: 41764738
Japanese encephalitis virus activates the NLRP3/caspase-1/GSDMD signaling pathway in dopaminergic neurons [ PLoS Negl Trop Dis, 2026, 20(1):e0013924] PubMed: 41570044
Discovery of potent and selective inhibitors of human NLRP3 with a novel mechanism of action [ J Exp Med, 2025, 222(11)e20242403] PubMed: 40892070
LXR pathway drives hormonal response intensity in polycystic ovary syndrome [ EMBO Mol Med, 2025, 10.1038/s44321-025-00251-1] PubMed: 40399491
Peroxiredoxin 1 promotes intestinal inflammation by activating the NLRP3 inflammasome in macrophages through lysosomal disruption in Crohn's disease [ Cell Death Dis, 2025, 16(1):565] PubMed: 40715057
Co-exposure to polystyrene nanoplastics and glyphosate exacerbates NETs-mediated pyroptosis by activating the NLRP3 inflammasome in mouse liver [ Ecotoxicol Environ Saf, 2025, 302:118529] PubMed: 40554107
PRRSV-2 nsp2 Ignites NLRP3 inflammasome through IKKβ-dependent dispersed trans-Golgi network translocation [ PLoS Pathog, 2025, 21(1):e1012915] PubMed: 39869629
Avian coronavirus IBV-induced activation of the NLRP3-Caspase-1-IL-1β axis in renal collecting ducts contributes to nephropathogenesis [ J Virol, 2025, 99(12):e0146625] PubMed: 41334910

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

Jump to: